200
Participants
Start Date
October 11, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
Afamelanotide and NB-UVB Light
Patients will receive combination of NB-UVB twice weekly and afamelanotide every 3 weeks for 20 weeks.
NB-UVB Light
Patients will receive NB-UVB light twice per week for 20 weeks. Upon study completion, NB-UVB Light Arm participants will have the opportunity to enroll in an open-label extension phase of the study. In this extension phase, participants will undergo the same evaluations and assessments as the ones performed in the main part of the study under Afamelanotide and NB-UVB Light Arm.
CLINUVEL site, Birmingham
CLINUVEL site, Fresno
CLINUVEL site, Los Angeles
CLINUVEL site, Palo Alto
CLINUVEL site, San Diego
CLINUVEL Site, Washington D.C.
CLINUVEL site, Miami
CLINUVEL site, Miramar
CLINUVEL site, Alpharetta
CLINUVEL site, Augusta
CLINUVEL site, Chicago
CLINUVEL site, Baton Rouge
CLINUVEL site, Detroit
CLINUVEL site, Minneapolis
CLINUVEL site, Roseville
CLINUVEL Site, Lee's Summit
CLINUVEL site, Rochester
CLINUVEL site, Cleveland
CLINUVEL site, Philadelphia
CLINUVEL Site, Charleston
CLINUVEL site, Thompson's Station
CLINUVEL Site, Cedar Park
CLINUVEL site, Dallas
CLINUVEL site, Tyler
CLINUVEL site, Charlottesville
CLINUVEL site, La Réunion
CLINUVEL site, Nice
CLINUVEL site, Nairobi
CLINUVEL site, London
CLINUVEL site, Manchester
Clinuvel, Inc.
INDUSTRY